References
- Pearson K, Rodriguez F. Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations. Cardiol Ther. 2020;9:275–292. doi: 10.1007/s40119-020-00177-4
- Pasławska A, Tomasik PJ. Lipoprotein(a)-60 Years Later-What Do We Know? Cells. 2023;12(20):2472. doi: 10.3390/cells12202472
- Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. J Lipids. 2020;3491764. doi: 10.1155/2020/3491764
- Iannuzzo G, Tripaldella M, Mallardo V, et al. Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Therapy. Biomedicines. 2021;9:838. doi: 10.3390/biomedicines9070838
- Tada H, Takamura M, Kawashiri MA. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb. 2019;26:583–591. doi: 10.5551/jat.RV17034
- Berman AN, Blankstein R. Current and future role of lipoprotein(a) in preventive cardiology. Curr Opin Cardiol. 2019;34:514–518. doi: 10.1097/HCO.0000000000000661
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455
- Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis. 2019;291:62–70. doi: 10.1016/j.atherosclerosis.2019.10.011
- Koschinsky ML, Kronenberg F. The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target. Atherosclerosis. 2022;349:1–6. doi: 10.1016/j.atherosclerosis.2022.04.017
- Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein(a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. Am J Cardiol. 2020;126:94–102. doi: 10.1016/j.amjcard.2020.03.043
- Enkhmaa B, Petersen KS, Kris-Etherton PM, et al. Diet and Lp(a): Does dietary change modify residual cardiovascular risk conferred by Lp(a)? Nutrients. 2020;12:2024. doi: 10.3390/nu12072024
- Bhatia HS, Wilkinson MJ. Lipoprotein(a): Evidence for role as a Causal Risk Factor in cardiovascular Disease and Emerging Therapies. J Clin Med. 2022;11:6040. doi: 10.3390/jcm11206040
- Kronenberg F. Lipoproteina(a). Handb Exp Pharmacol. 2022;270:201–232. doi: 10.1007/164_2021_504
- Kohn B, Ashraf AP, Wilson DP. Should Lipoprotein(a) be Measured in Youth? J Pediatr. 2021;228:285–289. doi: 10.1016/j.jpeds.2020.08.042
- Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022;349:53–62. doi: 10.1016/j.atherosclerosis.2022.04.006
- Hopewell JC, Haynes R, Baigent C. The role of lipoprotein(a) in chronic kidney disease. J Lipid Res. 2018;59:577–585. doi: 10.1194/jlr.R083626
- Gitto S, Cicero AFG, Logg E, et al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann Hepatol. 2018;17:64–75. doi: 10.5604/01.3001.0010.7536
- Telyuk P, Austin D, Luvai A, et al. Lipoprotein(a): Insights for the Practicing Clinician. J Clin Med. 2022;11:3673. doi: 10.3390/jcm11133673
- Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a Molehill? Atherosclerosis. 2022;349:123–135. doi: 10.1016/j.atherosclerosis.2022.04.008
- Banach M. Wytyczne PTL/KLRWP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce. 2021.
- Solnica B, Sygitowicz G, Sitkiewicz D, et al. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2020;16(2):237–252. doi: 10.5114/aoms.2020.93253
- Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13:374–392. doi: 10.1016/j.jacl.2019.04.010
- Stone NJ, Smith SC, Orringer CE, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:819–836. doi: 10.1016/j.jacc.2021.12.016
- Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: New insights from a large National Biobank. Arterioscler Thromb Vasc Biol. 2021;41:465–474. doi: 10.1161/ATVBAHA.120.315291
- Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study. J Am Coll Cardiol. 2022;79:1579–1590. doi: 10.1016/j.jacc.2022.02.018
- Langsted A, Nordestgaard BG, Kamstrup PR. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. J Am Coll Cardiol. 2019;74:54–66. doi: 10.1016/j.jacc.2019.03.524
- Larsson SC, Gill D, Mason AM, et al. Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease. Circulation. 2020;141:1826–1828. doi: 10.1161/CIRCULATIONAHA.120.045826
- Anagnostis P, Antza C, Trakatelli C, et al. The effect of menopause on lipoprotein(a) concentrations: a systematic review and meta-analysis. Maturitas. 2023;167:39–45. doi: 10.1016/j.maturitas.2022.09.012
- Anagnostis P, Galanis P, Chatzistergiou V, et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis. Maturitas. 2017;27–36. doi: 10.1016/j.maturitas.2017.02.009
- Stiekema LCA, Prange KHM, Hoogeveen RM, et al. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Eur Heart J. 2020;41:2262–2271. doi: 10.1093/eurheartj/ehaa171
- O'Donoghue ML, López JAG, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoprotein(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022;251:61–69. doi: 10.1016/j.ahj.2022.05.004
- Waldmann E, Parhofer KG. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). Pathology. 2019;51:227–232. doi: 10.1016/j.pathol.2018.10.016
- Sachais BS, Shaz BH. Apheresis to mitigate atherosclerotic vascular disease. Am J Hypertens. 2018;31:945–949. doi: 10.1093/ajh/hpy068
- Pokrovsky SN, Afanasieva OI, Ezhov MV. Therapeutic apheresis for management of Lp(a) hyperlipoproteinemia. Curr Atheroscler Rep. 2020;22:68. doi: 10.1007/s11883-020-00886-0
- O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk insights from the FOURIER trial. Circulation. 2019;139:1483–1492. doi: 10.1161/CIRCULATIONAHA.118.037184
- Bittner VA, Szarek M, Aylward PE, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75:133–144. doi: 10.1016/j.jacc.2019.10.057
- Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382:1520–1530. doi: 10.1056/NEJMoa1913805
- Koutsogianni A, Liamis G, Liberopoulos E, et al. Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications. Pharmaceuticals. 2023;16:750. doi: 10.3390/ph16050750
- Kronenberg F, Mora S, Stroes E, et.al. From the EAS: frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023;374(Suppl 1). doi: 10.1016/j.atherosclerosis.2023.04.012
- Masson W, Waisman G, Corral P, et.al. Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation. High Blood Press Cardiovasc Prev. 2024. doi: 10.1007/s40292-024-00649-x
- Hadi A, Askarpour M, Ziaei R, et al. Impact of flaxseed supplementation on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2020;34:1599–1608. doi: 10.1002/ptr.6640